XIAOMING JIA to Cardiovascular Diseases
This is a "connection" page, showing publications XIAOMING JIA has written about Cardiovascular Diseases.
Connection Strength
3.975
-
Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2023 11 09; 30(16):1731-1740.
Score: 0.370
-
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Vasc Health Risk Manag. 2022; 18:555-566.
Score: 0.338
-
Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2022 06; 350:82-89.
Score: 0.333
-
Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
Score: 0.320
-
Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affair Healthcare System. Cardiovasc Drugs Ther. 2022 04; 36(2):295-300.
Score: 0.306
-
Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women. J Clin Endocrinol Metab. 2020 12 01; 105(12).
Score: 0.302
-
Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. Curr Atheroscler Rep. 2020 10 03; 22(12):72.
Score: 0.299
-
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date. Vasc Health Risk Manag. 2020; 16:1-10.
Score: 0.284
-
Highlights from Selected Cardiovascular Disease Prevention Studies Presented at the 2019 European Society of Cardiology Congress. Curr Atheroscler Rep. 2019 11 19; 21(12):46.
Score: 0.281
-
Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials. Curr Atheroscler Rep. 2019 01 10; 21(1):1.
Score: 0.265
-
Poststatin Lipid Therapeutics: A Review. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):32-38.
Score: 0.265
-
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovasc Drugs Ther. 2018 02; 32(1):65-72.
Score: 0.248
-
Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. Genet Med. 2021 12; 23(12):2404-2414.
Score: 0.079
-
Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. Popul Health Manag. 2022 02; 25(1):39-45.
Score: 0.078
-
Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
Score: 0.071
-
Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2019 05 24; 21(8):31.
Score: 0.068
-
Statin use in carnitine palmitoyltransferase II deficiency. J Clin Lipidol. 2019 Jul - Aug; 13(4):550-553.
Score: 0.068